
|Articles|August 18, 2012
Biosimilars: Overview of Legislation, Policy, and Current State of Implementation
Advertisement
Enduring Webcast: Biosimilars: Overview of Legislation, Policy and Current State of Implementation
This webcast was brought to you by Amgen.
The faculty for this webcast:
- Defined therapeutic equivalence for small molecule generics
- Described how biologics differ from small molecule drugs
- Explained how the Biologics Price Control and Innovation Act amends the Public Health Service Act and the key requirements of the US biosimilars pathway
- Discussed the difference between biosimilarity and interchangeability
- Reviewed the US legislation for intellectual property and payment provisions
Length of webcast: 14 minutes
System Requirements
PC-based attendees
Required: Windows® 7, Vista, XP, 2003 Server or 2000
Macintosh®-based attendees
Required: Mac OS® X 10.4.11 (Tiger®) or newer
70575-R1-V1
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Government Shutdown Could Disrupt Health Care Access
2
Maternal, Child Mortality Higher in the US Compared With Majority of High-Income Countries
3
Colon Cancer Recurrence Risk Nearly Gone After 6 Years, Study Reveals
4
Lurbinectedin Combo Approved by FDA for Extensive-Stage Small Cell Lung Cancer
5